PerioTrap Pharmaceuticals

Molecular inhibitor against periodontitis

PerioTrap Logo
About PerioTrap Pharmaceuticals

Innovation in the dental sector

PerioTrap Pharmaceuticals GmbH is developing a selective active ingredient against a target enzyme found exclusively in the main pathogens causing periodontitis. Selective targeting and a novel application mechanism for targeted use at the site of infection can eliminate the need for conventional broad-spectrum antibiotics and minimize the impact on the natural oral flora. Chronic disease states are thus overcome and side effects reduced.

bmp Ventures Team

Andreas van Bon

Founded

2019

Invested

2020

Stage

Seed

Industry

Life Sciences

Status

Aktiv